Dermatoses as an iatrogenic complication of invasive device-based procedures

Background. In modern cosmetology, high-intensity energy-based technologies, which utilize the interaction of physical modalities with biological tissues, are effectively and widely used. These manipulations will disrupt the epithelial barrier, activating the tissue regeneration process. In some cases, adverse events or iatrogenic complications may develop, requiring additional medical intervention. Dermatitis after invasive device-based procedures can arise from clinician non-compliance with treatment protocols or patient non-adherence during the post-procedure recovery period. Allergic contact dermatitis (CD) and irritant CD can have similar clinical manifestations. Therapeutic strategies rely on two primary components: elimination of the factors that trigger the inflammatory process and active suppression of inflammation. Currently, topical corticosteroids are the gold standard of therapy, in alignment with Russian and international guidelines. It is optimal to use non-halogenated topical corticosteroids, such as methylprednisolone aceponate 0.1%. The selection of this agent is driven by its proven efficacy, favorable safety profile, and suitability for application on sensitive skin areas. Objective. To demonstrate a management strategy for patients with irritant CD and allergic CD caused by laser therapy. Material and methods. This study presents photographs illustrating the treatment outcomes of three patients. Methylprednisolone aceponate 0.1% cream was used. Results. Clinical observations in all presented cases demonstrated successful resolution of the pathological process with the use of methylprednisolone aceponate 0.1% cream, showing an absence of adverse effects and high patient satisfaction regarding its application. Conclusion. Methylprednisolone aceponate 0.1% cream was shown to be effective and safe both as monotherapy and in combination therapy for patients with irritant CD and allergic CD caused by laser therapy.